@article{6c0285ccd2c44571add658c0c71d78b3,
title = "The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension",
keywords = "BrigHTN, CIN-107, aldosterone, baxdrostat, blood pressure, clinical trial, hypertension, resistant hypertension",
author = "Imma Forzano and Pasquale Mone and Fahimeh Varzideh and Jankauskas, {Stanislovas S.} and Urna Kansakar and {De Luca}, Antonio and Gaetano Santulli",
note = "Funding Information: The Santulli{\textquoteright}s Lab is supported in part by the National Institutes of Health (NIH): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK: R01-DK123259, R01-DK033823), National Heart, Lung, and Blood Institute (NHLBI: R01-HL164772, R01-HL159062, R01-HL146691, T32-HL144456), National Center for Advancing Translational Sciences (NCATS: UL1TR002556-06) to GS, by the Monique Weill-Caulier and Irma T. Hirschl Trusts (to GS), and by the Diabetes Action Research and Education Foundation (to GS). FV is supported in part by a postdoctoral fellowship of the American Heart Association (AHA-22POST995561). SSJ is supported in part by a postdoctoral fellowship of the American Heart Association (AHA-21POST836407). ",
year = "2022",
month = dec,
day = "9",
doi = "10.3389/fendo.2022.1097968",
language = "English (US)",
volume = "13",
journal = "Frontiers in Endocrinology",
issn = "1664-2392",
publisher = "Frontiers Media S. A.",
}
